Arafarma Group constantly studies, researches and develops answers to the problems of human beings with the aim of improving people’s quality of life, safety and welfare. The scientific organisation and capacity available to Arafarma Group has enabled the team of research technicians to successfully develop medicines, medical devices, dietary products, nutritional supplements and dermopharmacy products.
This development involves a series of steps that include obtaining molecules, pharmaco-toxicological studies, pharmaceutical development and clinical trials to demonstrate safety and efficacy.
The Arafarma Group research area is divided into the following departments:
A group of scientists and sales agents with extensive professional experience that evaluate potential alternatives that are appearing for product development.
Development of synthesis, processes and synthesis intermediates for the production of the desired molecules in the laboratory, in the pilot plant and industrial plant, with subsequent characterisation, analysis and control, all followed by the Department of Quality Assurance, with the aim of having an EDMF and production under GMP standards.
We focus on studying the activity of potential molecules for future selection, based on the selection of possible new active ingredients and the results of its pharmacodynamic, toxicological and pharmacokinetic characteristics via the appropriate preclinical studies.
These results meet expectations expected by the group of scientists from the Department of Discovery.
It focuses on the development of the best pharmaceutical forms that make it possible to vectorise the active ingredients so they have maximum effectiveness and tolerance. Together with the scientific and sales area this department studies the selection of the dosage form, the election of the excipients, the desirable physico-chemical and organoleptic characteristics and best stability of the active ingredient. In addition, the originality of the pharmaceutical presentation is evaluated which enhances the adherence and compliance of the dosage regimen, thereby differentiating us from other competitors on the market.
It focuses on the design and implementation of studies required to demonstrate the safety and efficacy of the products developed before marketing. In addition, Phase I, Phase II and Phase III clinical studies are performed at appropriate centres that are required for the processing of authorisations and statistical analyses of the results, which will support confidence in the product and its marketing authorisation.
The strategic lines for Arafarma Group’s product development are the following: